These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 34677796)

  • 21. Compendium of aberrant DNA methylation and histone modifications in cancer.
    Hattori N; Ushijima T
    Biochem Biophys Res Commun; 2014 Dec; 455(1-2):3-9. PubMed ID: 25194808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic pathways and glioblastoma treatment: insights from signaling cascades.
    Allen BK; Stathias V; Maloof ME; Vidovic D; Winterbottom EF; Capobianco AJ; Clarke J; Schurer S; Robbins DJ; Ayad NG
    J Cell Biochem; 2015 Mar; 116(3):351-63. PubMed ID: 25290986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
    Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
    Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The promise of epigenetic therapy: reprogramming the cancer epigenome.
    Kelly AD; Issa JJ
    Curr Opin Genet Dev; 2017 Feb; 42():68-77. PubMed ID: 28412585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenomics, Pharmacoepigenomics, and Personalized Medicine in Cervical Cancer.
    Kabekkodu SP; Chakrabarty S; Ghosh S; Brand A; Satyamoorthy K
    Public Health Genomics; 2017; 20(2):100-115. PubMed ID: 28521327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmaco-epigenomics: On the Road of Translation Medicine.
    López-Camarillo C; Gallardo-Rincón D; Álvarez-Sánchez ME; Marchat LA
    Adv Exp Med Biol; 2019; 1168():31-42. PubMed ID: 31713163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Developmental origins and oncogenic pathways in malignant brain tumors.
    Lu QR; Qian L; Zhou X
    Wiley Interdiscip Rev Dev Biol; 2019 Jul; 8(4):e342. PubMed ID: 30945456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diffuse midline glioma: review of epigenetics.
    Cooney TM; Lubanszky E; Prasad R; Hawkins C; Mueller S
    J Neurooncol; 2020 Oct; 150(1):27-34. PubMed ID: 32804378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations in chromatin machinery and pediatric high-grade glioma.
    Lulla RR; Saratsis AM; Hashizume R
    Sci Adv; 2016 Mar; 2(3):e1501354. PubMed ID: 27034984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies.
    Waitkus MS; Yan H
    Clin Cancer Res; 2021 Jan; 27(2):383-388. PubMed ID: 32883741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long non-coding RNAs in brain tumours: Focus on recent epigenetic findings in glioma.
    Pop S; Enciu AM; Necula LG; Tanase C
    J Cell Mol Med; 2018 Oct; 22(10):4597-4610. PubMed ID: 30117678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas.
    Rajendran G; Shanmuganandam K; Bendre A; Muzumdar D; Goel A; Shiras A
    J Neurooncol; 2011 Sep; 104(2):483-94. PubMed ID: 21229291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histone Modifying Enzymes and Chromatin Modifiers in Glioma Pathobiology and Therapy Responses.
    Ciechomska IA; Jayaprakash C; Maleszewska M; Kaminska B
    Adv Exp Med Biol; 2020; 1202():259-279. PubMed ID: 32034718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic alterations in cancer.
    Ilango S; Paital B; Jayachandran P; Padma PR; Nirmaladevi R
    Front Biosci (Landmark Ed); 2020 Mar; 25(6):1058-1109. PubMed ID: 32114424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug Repurposing in Pediatric Brain Tumors: Posterior Fossa Ependymoma and Diffuse Midline Glioma under the Looking Glass.
    Servidei T; Sgambato A; Lucchetti D; Navarra P; Ruggiero A
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):77. PubMed ID: 37114548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigational new drugs for brain cancer.
    Staedtke V; Bai RY; Laterra J
    Expert Opin Investig Drugs; 2016 Aug; 25(8):937-56. PubMed ID: 27170161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transitioning from genotypes to epigenotypes: why the time has come for medulloblastoma epigenomics.
    Batora NV; Sturm D; Jones DT; Kool M; Pfister SM; Northcott PA
    Neuroscience; 2014 Apr; 264():171-85. PubMed ID: 23876321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetics and cancer, 2nd IARC meeting, Lyon, France, 6 and 7 December 2007.
    Lambert MP; Herceg Z
    Mol Oncol; 2008 Jun; 2(1):33-40. PubMed ID: 19383327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic aberrations in malignant gliomas: an open door leading to better understanding and treatment.
    Martinez R; Schackert G
    Epigenetics; 2007; 2(3):147-50. PubMed ID: 18063907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic Modifications in Neurological Diseases: Natural Products as Epigenetic Modulators a Treatment Strategy.
    Gangisetty O; Murugan S
    Adv Neurobiol; 2016; 12():1-25. PubMed ID: 27651245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.